BridgeBio Oncology Therapeutics Inc.
BBOTBridgeBio Oncology Therapeutics Inc.
NASDAQ
Healthcare
Biotechnology
$8.92
-0.11(-1.22%)
52W $8.68 – $13.73
AI-generated
BridgeBio Oncology Therapeutics Inc.
$714MMkt Cap
—Rev TTM
-$344MNI TTM
-2.0xP/E TTM
Latest Earnings
10-K
FY FY2025Mar 4, 2026BridgeBio Oncology Therapeutics Inc. (BBOT) reported a net loss of $134.0 million for fiscal year 2025, compared to a net loss of $74.3 million in the prior year, reflecting increased investment in its clinical-stage oncology pipeline. The company generated no revenue, as it has no approved products, and incurred total operating expenses of $145.8 million, primarily driven by research and...
What Changed Recently
Fundamentals
How The Business Makes Money
BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.
Industry Biotechnology
Analyst View
Company Profile
CIK0001869105
ISINUS1079241022
Phone650 405 4770
Address256 E. Grand Avenue, South San Francisco, CA, 94080, US
SEC EDGAR